IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · Real-Time Price · USD
1.180
-0.020 (-1.67%)
At close: Nov 4, 2024, 4:00 PM
1.190
+0.010 (0.85%)
After-hours: Nov 4, 2024, 4:36 PM EST
IO Biotech Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for IO Biotech stock have an average target of 9.33, with a low estimate of 6.00 and a high estimate of 12. The average target predicts an increase of 690.68% from the current stock price of 1.18.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 16, 2024.
Analyst Ratings
The average analyst rating for IO Biotech stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +408.47% | Sep 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +916.95% | Sep 16, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $10 | Buy | Maintains | $10 | +747.46% | Sep 3, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $7 → $4 | Buy | Maintains | $7 → $4 | +238.98% | Sep 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +916.95% | Sep 3, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.20M
EPS This Year
-1.20
from -1.98
EPS Next Year
-1.20
from -1.20
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 4.9M | 48.8M | ||
| Avg | n/a | 1.2M | 25.8M | ||
| Low | n/a | n/a | 12.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 3,970.9% | ||
| Avg | - | - | 2,049.0% | ||
| Low | - | - | 913.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.04 | -1.07 | -0.91 | ||
| Avg | -1.20 | -1.20 | -1.24 | ||
| Low | -1.29 | -1.42 | -1.77 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.